Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 2065-2072

  Bosetti, C ^a   Rosato, V ^a   Li, D ^b   Silverman, D ^c   Petersen, G M ^d   Bracci, P M ^e   Neale, R E ^f   Muscat, J ^g   Anderson, K ^h   Gallinger, S ⁱ   Olson, S H ^j   Miller, A B ^k   Bas Bueno de Mesquita, H ^l,m,n   Scelo, G ^o   Janout, V ^p   Holcatova, I ^q   Lagiou, P ^r,s   Serraino, D ^t   Lucenteforte, E ^u   Fabianova, E ^v   Baghurst, P A ^w   Zatonski, W ^x   Foretova, L ^y   Fontham, E ^z   Bamlet, W R ^d   Holly, E A ^e   Negri, E ^a   Hassan, M ^b   Prizment, A ^h   Cotterchio, M ^k,aa   Cleary, S ⁱ   Kurtz, R C ^j   Maisonneuve, P ^ab   Trichopoulos, D ^r   Polesel, J ^t   Duell, E J ^ac   Boffetta, P ^ad   La Vecchia, C ^ae   Ghadirian, P ^af   more..

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^g PENNSYLVANIA STATE UNIVERSITY   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k UNIVERSITY OF TORONTO   (Canada)

^l NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^m UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁿ IMPERIAL COLLEGE LONDON   (United Kingdom)

^o INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^p PALACKÝ UNIVERSITY   (Czech Republic)

^q CHARLES UNIVERSITY   (Czech Republic)

^r HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^s UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^t CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^u UNIVERSITY OF FLORENCE   (Italy)

^v Regional Authority of Public Health in Banska Bystrica   (Slovakia)

^w WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^x INSTITUTE OF ONCOLOGY   (Poland)

^y MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^z Department of Pathology   (United States)

^aa CANCER CARE ONTARIO   (Canada)

^ab EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^ac CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^ad MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^ae UNIVERSITY OF MILAN   (Italy)

^af NONE

more..

Author keywords

case control study; diabetes; insulin; oral antidiabetics; pancreatic cancer; pooled analysis

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ADULT; AGED; CASE CONTROL STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; RISK FACTOR; SMOKING; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LOGISTIC MODELS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RISK FACTORS; SMOKING;

EID: 84924610155     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu276     Document Type: Article

References (50)

1. Ferlay, J., Shin, H.R., Bray, F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127 (2010), 2893–2917.
2. Klint, A., Engholm, G., Storm, H.H., et al. Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol 49 (2010), 578–607.
3. Maisonneuve, P., Lowenfels, A.B., Epidemiology of pancreatic cancer: an update. Dig Dis 28 (2010), 645–656.
4. Everhart, J., Wright, D., Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273 (1995), 1605–1609.
5. Huxley, R., Ansary-Moghaddam, A., Berrington de Gonzalez, A., et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92 (2005), 2076–2083.
6. Giovannucci, E., Harlan, D.M., Archer, M.C., et al. Diabetes and cancer: a consensus report. Diabetes Care 33 (2010), 1674–1685.
7. Ben, Q., Xu, M., Ning, X., et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 47 (2011), 1928–1937.
8. Li, D., Diabetes and pancreatic cancer. Mol Carcinog 51 (2012), 64–74.
9. Batabyal, P., Vander Hoorn, S., Christophi, C., Nikfarjam, M., Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies. Ann Surg Oncol 21 (2014), 2453–2462.
10. Li, D., Tang, H., Hassan, M.M., et al. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 22 (2011), 189–197.
11. Elena, J.W., Steplowski, E., Yu, K., et al. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control 24 (2013), 13–25.
12. Soranna, D., Scotti, L., Zambon, A., et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17 (2012), 813–822.
13. Bosetti, C., Rosato, V., Buniato, D., et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 18 (2013), 148–156.
14. Luckett, B.G., Su, L.J., Rood, J.C., Fontham, E.T., Cadmium exposure and pancreatic cancer in south Louisiana. J Environ Public Health, 2012, 2012, 180186.
15. McWilliams, R.R., Bamlet, W.R., de Andrade, M., et al. Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L. Cancer Epidemiol Biomarkers Prev 18 (2009), 1295–1302.
16. Hassan, M.M., Bondy, M.L., Wolff, R.A., et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 102 (2007), 2696–2707.
17. Olson, S.H., Orlow, I., Simon, J., et al. Allergies, variants in IL-4 and IL-4R alpha genes, and risk of pancreatic cancer. Cancer Detect Prev 31 (2007), 345–351.
18. Silverman, D.T., Schiffman, M., Everhart, J., et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 80 (1999), 1830–1837.
19. Muscat, J.E., Stellman, S.D., Hoffmann, D., Wynder, E.L., Smoking and pancreatic cancer in men and women. Cancer Epidemiol Biomarkers Prev 6 (1997), 15–19.
20. Anderson, L.N., Cotterchio, M., Gallinger, S., Lifestyle, dietary, and medical history factors associated with pancreatic cancer risk in Ontario, Canada. Cancer Causes Control 20 (2009), 825–834.
21. Wang, F., Gupta, S., Holly, E.A., Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev 15 (2006), 1458–1463.
22. Henry, S.A., Prizment, A.E., Anderson, K.E., Duration of diabetes and pancreatic cancer in a case-control study in the Midwest and the Iowa Women's Health Study (IWHS) cohort. JOP 14 (2013), 243–249.
23. Urayama, K.Y., Holcatova, I., Janout, V., et al. Body mass index and body size in early adulthood and risk of pancreatic cancer in a central European multicenter case-control study. Int J Cancer 129 (2011), 2875–2884.
24. Kalapothaki, V., Tzonou, A., Hsieh, C.C., et al. Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control 4 (1993), 375–382.
25. Bosetti, C., Rosato, V., Polesel, J., et al. Diabetes mellitus and cancer risk in a network of case-control studies. Nutr Cancer 64 (2012), 643–651.
26. La Vecchia, C., Negri, E., Franceschi, S., et al. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 70 (1994), 950–953.
27. Tran, B., Whiteman, D.C., Webb, P.M., et al. Association between ultraviolet radiation, skin sun sensitivity and risk of pancreatic cancer. Cancer Epidemiol 37 (2013), 886–892.
28. Maisonneuve, P., Lowenfels, A.B., Bueno-de-Mesquita, H.B., et al. Past medical history and pancreatic cancer risk: results from a multicenter case-control study. Ann Epidemiol 20 (2010), 92–98.
29. Breslow, N.E., Day, N.E., Statistical methods in cancer research, volume I: the analysis of case-control studies. 1980, IARC, Lyon, France IARC Sci Publ No. 32.
30. Sah, R.P., Nagpal, S.J., Mukhopadhyay, D., Chari, S.T., New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 10 (2013), 423–433.
31. Permert, J., Ihse, I., Jorfeldt, L., et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 159 (1993), 101–107.
32. Chari, S.T., Leibson, C.L., Rabe, K.G., et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134 (2008), 95–101.
33. Pannala, R., Leirness, J.B., Bamlet, W.R., et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134 (2008), 981–987.
34. Permert, J., Adrian, T.E., Jacobsson, P., et al. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor?. Am J Surg 165 (1993), 61–66 discussion 66–67.
35. Cersosimo, E., Pisters, P.W., Pesola, G., et al. Insulin secretion and action in patients with pancreatic cancer. Cancer 67 (1991), 486–493.
36. Nakamori, S., Ishikawa, O., Ohigashi, H., et al. Increased blood proinsulin and decreased C-peptide levels in patients with pancreatic cancer. Hepatogastroenterology 46 (1999), 16–24.
37. Permert, J., Ihse, I., Jorfeldt, L., et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 80 (1993), 1047–1050.
38. Giovannucci, E., Michaud, D., The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132 (2007), 2208–2225.
39. Wolpin, B.M., Bao, Y., Qian, Z.R., et al. Hyperglycemia, insulin resistance, impaired pancreatic beta-cell function, and risk of pancreatic cancer. J Natl Cancer Inst 105 (2013), 1027–1035.
40. Fisher, W.E., Boros, L.G., Schirmer, W.J., Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res 63 (1996), 310–313.
41. Ding, X.Z., Fehsenfeld, D.M., Murphy, L.O., et al. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas 21 (2000), 310–320.
42. Pollak, M., Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8 (2008), 915–928.
43. Rohrmann, S., Giovannucci, E., Smit, E., Platz, E.A., Association of IGF-1 and IGFBP-3 with lower urinary tract symptoms in the third national health and nutrition examination survey. Prostate 67 (2007), 1693–1698.
44. Renehan, A.G., Tyson, M., Egger, M., et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371 (2008), 569–578.
45. Stevens, R.J., Roddam, A.W., Beral, V., Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 96 (2007), 507–509.
46. Bonelli, L., Aste, H., Bovo, P., et al. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas 27 (2003), 143–149.
47. Dowling, R.J., Goodwin, P.J., Stambolic, V., Understanding the benefit of metformin use in cancer treatment. BMC Med, 9, 2011, 33.
48. Pannala, R., Leibson, C.L., Rabe, K.G., et al. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 104 (2009), 2318–2325.
49. Bosetti, C., Tavani, A., Negri, E., et al. Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. J Clin Epidemiol 54 (2001), 902–906.
50. Cavanaugh, K.L., Merkin, S.S., Plantinga, L.C., et al. Accuracy of patients’ reports of comorbid disease and their association with mortality in ESRD. Am J Kidney Dis 52 (2008), 118–127.